NRIX - מחיר רכישת החברה nurixtx.com

Nurix Therapeutics (NRIX) is a pioneer in developing targeted protein degradation methods to combat tumors, where multi-million dollar agreements with pharma behemoths guarantee a steady cash flow and positive FCF. The price action based on Separate Enterprise Value is 1995.22. The company generates revenue through innovative alliances in inflammation and cancer therapy, leveraging immense credibility with the industry's largest players.

A defensive portfolio requires a strict selection of assets based on long-term maturity. Enterprise value is calculated as the sum of market capitalization and net debt, determining the actual cost of a full business buyout. For Nurix Therapeutics (NRIX), this metric is stabilized by multi-billion dollar partnerships with pharma behemoths that offset operating expenses. Such a capital structure minimizes stagnation risks. The price action of the business's net market price confirms the issuer's fundamental stability.